EBV NA IgG ELISA Kit

Produktnummer ABIN996988

Produktdetails EBV NA IgG ELISA Kit

Target: EBV NA IgG (Anti-Epstein-Barr Virus Nuclear Antigen IgG (EBV NA IgG))

Reaktivität: Epstein-Barr Virus (EBV)

Nachweismethode: Colorimetric

Methodentyp: Competition ELISA

Applikation: ELISA

Verwendungszweck: Epstein-Barr Virus Nuclear Antigen (EBNA-1) IgG Enzyme- Linked Immunosorbent Assay (ELISA) is intended for the qualitative and semi-quantitative determination of IgG antibody in human serum to EBNA-1 recombinant antigen.

Proben: Serum

Analytische Methode: Qualitative and Semi-Quantitative

Spezifität: 100%

Sensitivität: 97.8 %

Anwendungsinformationen

Probenmenge: 100 μL

Testdauer: 1 h

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Haltbarkeit: 18 months

Details zu EBV NA IgG

Target: EBV NA IgG (Anti-Epstein-Barr Virus Nuclear Antigen IgG (EBV NA IgG))

Andere Bezeichnung: Epstein Barr Virus Nuclear Antigen (EBNA) IgG (EBV NA IgG Produkte)

Substanzklasse: Antibody

Hintergrund: Epstein-Barr virus (EBV) is a common human pathogen, affecting 80% of adults in the US. Since the discovery of Epstein-Barr virus in 1964, EBV has been etiologically implicated in an increasing number of human diseases, such as infectious mononucleosis, Burkitt's lymphoma and nasopharyngeal carcinoma. EBV has also been associated with B cell lymphomas in immunosuppressed individuals, including both transplant patients and patients with AIDS. EBV is classified as a member of the herpesvirus family based upon its characteristic morphology. All herpesviruses share the ability to establish a latent infection in their hosts. Although primary infection with EBV during childhood is usually asymptomatic, nearly one-half to two-thirds of primary infections with the virus in older adolescents and young adults result in overt clinical disease such as infectious mononucleosis (IM). Infectious mononucleosis is an acute, self-limited lympho-proliferative disease caused by EBV. When primary infection is delayed until young adulthood and adolescence, however, there is about a 50% chance that it will occur with the classic clinical manifestations associated with IM.

Infection of the target cells leads to two forms of viral cycles: 1) latent, nonproductive and 2) productive, replicative infections. In both cycles, one of the earliest antigens expressed is lymphocyte-detected membrane antigen, a cell-surface antigen recognized by T-cells. It has been well established that most individuals exposed to EBV develop a heterophile antibody response. Expression of EBNA-1 either follows or parallels membrane antigen at 12 to 24 hours post infection. EBNA-1 is found as nonstructural, intranuclear antigen(s), present in all EBV-transformed cell lines as in tumors from Burkitt's and nasopharyngeal carcinoma patients. In the fully productive, replicative cycle, the synthesis of antigen follows EBNA-1. The viral capsid antigen complex (VCA) appears late in the replicative cycle. It has recently become apparent that EBNA-1 is probably not a single antigenic moiety, but a multicomponent antigen complex, on the basis of reactivities of sera from different classes of patients. The major component EBNA-1 has been purified and sequenced in its entirety.
Antibody levels of EBNA-1 IgG, are diagnostic in determining acute and convalescent stages in IM. IgG antibodies to EBNA-1 are rarely present in acute IM and rise during convalescence. They will rise to a plateau level in three months to a year and will normally persist for life. The DAI EBNA-1 IgG kit utilizes the ELISA technology where a purified recombinant EBNA-1 antigen is bound to the wells of a microplate. A peroxidase coupled anti-human IgG conjugate is used as the detection system.